James Cassidy
Overview
Explore the profile of James Cassidy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
2036
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Porotnikov D, Harankahage D, Ellison C, Yang M, Cassidy J, Zamkov M
Nano Lett
. 2021 May;
21(11):4787-4794.
PMID: 34038138
We demonstrate that solution-phase semiconductor nanocrystals (NCs) undergo photoinduced rotation in an external electric field. Present measurements backed by theoretical calculations show that the rotation of colloidal NCs is driven...
12.
Porotnikov D, Diroll B, Harankahage D, Obloy L, Yang M, Cassidy J, et al.
Nanoscale
. 2020 Aug;
12(33):17426-17436.
PMID: 32797122
Colloidal semiconductor nanocrystals (NCs) represent a promising class of nanomaterials for lasing applications. Currently, one of the key challenges facing the development of high-performance NC optical gain media lies in...
13.
Knuutinen O, Pyle A, Suo-Palosaari M, Duff J, Froukh T, Lehesjoki A, et al.
Clin Genet
. 2020 Aug;
98(5):493-498.
PMID: 32779182
TATA-box binding protein associated factor, RNA polymerase I subunit C (TAF1C) is a component of selectivity factor 1 belonging to RNA polymerase I (Pol I) transcription machinery. We report two...
14.
Cassidy J, Zamkov M
J Chem Phys
. 2020 Mar;
152(11):110902.
PMID: 32199442
Nanoshell quantum dots (QDs) represent a novel class of colloidal semiconductor nanocrystals (NCs), which supports tunable optoelectronic properties over the extended range of particle sizes. Traditionally, the ability to control...
15.
Yang M, Moroz P, Jin Z, Budkina D, Sundrani N, Porotnikov D, et al.
J Am Chem Soc
. 2019 Jul;
141(28):11286-11297.
PMID: 31265269
Assemblies of metal nanostructures and fluorescent molecules represent a promising platform for the development of biosensing and near-field imaging applications. Typically, the interaction of molecular fluorophores with surface plasmons in...
16.
Graham J, Spiliopoulou P, Arbuckle R, Bridge J, Cassidy J
Patient Relat Outcome Meas
. 2017 Nov;
8:111-119.
PMID: 29089790
Background: Traditional endpoints in oncology are based on measuring the tumor size and combining this with a time factor. Current studies with immunotherapy show that even when median survival is...
17.
Park S, Goldstein D, Krishnan A, Lin C, Friedlander M, Cassidy J, et al.
CA Cancer J Clin
. 2014 Mar;
63(6):419-37.
PMID: 24590861
With a 3-fold increase in the number of cancer survivors noted since the 1970s, there are now over 28 million cancer survivors worldwide. Accordingly, there is a heightened awareness of...
18.
Becerra C, Salazar R, Garcia-Carbonero R, Thomas A, Vazquez-Mazon F, Cassidy J, et al.
Cancer Chemother Pharmacol
. 2014 Feb;
73(4):695-702.
PMID: 24488322
Purpose: Figitumumab (CP-751,871) is a human IgG2 monoclonal antibody that binds and down-regulates insulin-like growth factor receptor-1 (IGF-1R) and inhibits activation of this receptor by IGF-1 and IGF-2. This nonrandomized,...
19.
Cheung W, Shi Q, OConnell M, Cassidy J, Blanke C, Kerr D, et al.
Clin Colorectal Cancer
. 2013 Jul;
12(3):179-87.
PMID: 23810482
Purpose: To compare long-term outcomes between men and women in a large cohort of clinical trial participants with early-stage colon cancer, specifically by examining whether the prognostic effect of sex...
20.
Tabernero J, Garcia-Carbonero R, Cassidy J, Sobrero A, Van Cutsem E, Kohne C, et al.
Clin Cancer Res
. 2013 Mar;
19(9):2541-50.
PMID: 23532888
Purpose: This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC). Experimental Design: Patients were randomized to sorafenib (400 mg...